Home Featured Page 128

Featured

Latest

Pα+ Psychedelic Bulletin #213: Compass Accelerates Psilocybin Launch Planning; Australian VA Funds Psychedelic Therapy for Veterans; AbbVie Paid $900M Upfront for Psychedelic Candidate

Review: Colorado Psychedelic Cup 2025

Dr Ros Watts – Building Communities and Connection

The Psychedelic News Feed: October 27 – November 02, 2025

Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months

Clearmind Medicine Announces Closing of US$7.5 Million Public Offering and Uplisting...

Psychedelic Bulletin #124: MAPS Wraps Second Phase 3 MDMA Trial; Preparing...

Why Did Psychedelics Relieve My Chronic Pain?

Psychedelics Weekly – Oregon Measure 109: Approaching the Proposed Final Rules

MAPS Wraps Second Phase 3 Trial of MDMA-Assisted Therapy for PTSD

Racing Beyond Racemic: A Look at Ketamine Drug Development Ahead of...

Surprising Results: Psilocybin Trial for Depression Alleviates Chronic Pain

PT373 – Integrative Psychiatry & The Safety of At-Home Ketamine

Interview | Elliot Marseille, Global Initiative for Psychedelic Science Economics...

1...127128129...301 Page 128 of 301

Pα+ Psychedelic Bulletin #213: Compass Accelerates Psilocybin Launch Planning; Australian VA...

Review: Colorado Psychedelic Cup 2025

Dr Ros Watts – Building Communities and Connection

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Pα+ Psychedelic Bulletin #213: Compass Accelerates Psilocybin Launch Planning; Australian VA Funds Psychedelic Therapy for Veterans; AbbVie Paid $900M Upfront for Psychedelic Candidate

Review: Colorado Psychedelic Cup 2025

Dr Ros Watts – Building Communities and Connection

The Psychedelic News Feed: October 27 – November 02, 2025

Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months

Psychedelic Brains In A Dish

Clearmind Medicine Announces Closing of US$7.5 Million Public Offering and Uplisting...

Psychedelic Bulletin #124: MAPS Wraps Second Phase 3 MDMA Trial; Preparing...

Why Did Psychedelics Relieve My Chronic Pain?

Psychedelics Weekly – Oregon Measure 109: Approaching the Proposed Final Rules

MAPS Wraps Second Phase 3 Trial of MDMA-Assisted Therapy for PTSD

Racing Beyond Racemic: A Look at Ketamine Drug Development Ahead of...

Surprising Results: Psilocybin Trial for Depression Alleviates Chronic Pain

PT373 – Integrative Psychiatry & The Safety of At-Home Ketamine

Interview | Elliot Marseille, Global Initiative for Psychedelic Science Economics...

EDITOR PICKS

Pα+ Psychedelic Bulletin #213: Compass Accelerates Psilocybin Launch Planning; Australian VA...

Review: Colorado Psychedelic Cup 2025

Dr Ros Watts – Building Communities and Connection

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY